Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast Cancer
Howard A. "Skip" Burris, MD
Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.